NEUROCYTONIX
Curing the Incurable
NeuroCytonix is an emerging biomedical technology company founded in January 2017 to develop transformational medical technologies for regeneration of the nervous system.
REGROWING THE BRAIN
Currently we are conducting a double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of the NeuroCytotron in patients with cerebral palsy.
J. Roberto Trujillo, an MD and PhD from Harvard University, has worked on clinical and basic neuroscience research for over 25 years. He is the founder of NeuroCytonix.
NeuroCytonix technology and its related protocols are a new approach to the treatment of non-progressive neurodegenerative diseases such as stroke, cerebral palsy and traumatic brain injury.
First FDA controlled clinical trial for cerebral palsy currently in process.
link to NeuroCytonix clinical trial information in ClinicalTrials.gov
Our cutting-edge technology
neuron tissue engineering
NeuroCytonix has structured a team of 20 specialists in Monterrey, Mexico for cerebral palsy clinical trials.